SS Innovations International, Inc. (SSII) - 10-Q Summary
Business Context and Reporting Period
Company: SS Innovations International, Inc. (SSII)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: SSII designs, manufactures, and markets the "SSi Mantra" surgical robotic system and related instruments. The company operates primarily in India (93% of revenue for the six months ended June 30, 2026) with expanding international presence. The company is listed on the Nasdaq Capital Market under the ticker "SSII".
Key Financial Metrics
| Metric | Three Months Ended June 30, 2026 |
Six Months Ended June 30, 2026 |
Six Months Ended June 30, 2025 |
|---|---|---|---|
| Total Revenue | $13,939,709 | $25,041,075 | $15,120,915 |
| Gross Profit | $7,100,950 | $12,428,171 | $7,002,266 |
| Gross Margin | 50.9% | 49.6% | 46.3% |
| Net Loss | $(2,661,350) | $(6,243,921) | $(5,938,044) |
| Operating Loss | $(2,271,354) | $(5,896,932) | $(5,623,766) |
| Cash & Equivalents (End of Period) | $13,647,430 (June 30, 2026) | ||
| Restricted Cash (End of Period) | $9,023,593 (June 30, 2026) | ||
| Total Assets | $96,982,013 (June 30, 2026) | ||
| Total Liabilities | $43,580,790 (June 30, 2026) | ||
| Stockholders' Equity | $53,401,223 (June 30, 2026) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 39.4% for the six months ended June 30, 2026, compared to the prior year period, driven by higher sales of SSi Mantra 3 systems and instruments.
- Expense Increases:
- R&D Expenses: Increased 125% ($3.39M vs $1.51M) due to clinical trials and regulatory activities for FDA and CE Mark approvals.
- SG&A Expenses: Increased 35% ($8.94M vs $6.64M) due to legal fees, Nasdaq uplisting costs, and business events.
- Stock-Based Compensation: Increased 33% ($5.32M vs $4.01M) due to new Restricted Share Awards and advisory share vesting.
- Net Loss: Net loss increased slightly by 5.1% for the six-month period, despite significant revenue growth, due to the aforementioned expense increases.
- Liquidity: Cash and cash equivalents increased significantly from $3.2M at year-end 2025 to $13.6M at June 30, 2026, bolstered by a private placement.
Guidance, Outlook, Risks, and Unusual Items
- Capital Raise: In March 2026, the company completed a private placement raising net proceeds of $18.45 million. Proceeds are designated for working capital, growth initiatives in India, and preparation for US/EU market entry.
- Going Concern: The filing includes a "Going Concern" warning. Despite the recent capital raise, management states that existing cash resources and operating income are not expected to be sufficient to fund operations for the next 12 months without further funding.
- Regulatory Outlook: The company is actively pursuing FDA clearance and EU CE Mark certification, which are critical for future expansion.
- Internal Controls: The company disclosed material weaknesses in internal controls over financial reporting, including inadequate design of controls for U.S. GAAP application and lack of written documentation. Remediation efforts, including ERP implementation, are underway.
- Tax Contingency: A pending transfer pricing dispute with Indian tax authorities involves a proposed adjustment of approximately $501,000. Management believes its position will be sustained and has not accrued a liability.
Investor Verification Checklist
- Cash Burn Rate: Verify the sufficiency of the $18.45M private placement proceeds against the stated 12-month funding gap and current operating cash burn.
- Regulatory Milestones: Monitor progress on FDA and CE Mark approvals, as these are prerequisites for significant revenue expansion outside India.
- Internal Control Remediation: Track the implementation of the new cloud-based ERP system and the resolution of material weaknesses in financial reporting.
- Revenue Concentration: Assess the risk associated with 93% of revenue being derived from India and the timeline for diversifying into US/EU markets.
- Debt Covenants: Review the terms of the bank overdraft facilities (secured by fixed deposits and personal guarantees) to ensure compliance with financial covenants.